SCHEMBL18177424

SCHEMBL18177424

N#Cc1cccc(NC(=O)c2cncc(-c3cccnc3)n2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 3/20 0.68
SCN2A Q99250 5/20 0.61
SCN10A Q9Y5Y9 5/20 0.61
GRM4 Q14833 1/20 0.57
PPARG P37231 1/20 0.55
ABL1 P00519 2/20 0.55
BCR P11274 2/20 0.55
PDGFRB P09619 1/20 0.55
PDGFRA P16234 1/20 0.55
PRKCA P17252 1/20 0.55
BRAF P15056 1/20 0.50
GRM5 P41594 2/20 0.49
SRC P12931 1/20 0.49
PRKDC P78527 1/20 0.49
CYP11B1 P15538 1/20 0.49
CYP11B2 P19099 1/20 0.49
EGLN1 Q9GZT9 1/20 0.48
IRAK4 Q9NWZ3 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16489055 0.86 ATR (0.65) ATRSCN2ASCN10AGRM4BRAF
SCHEMBL16420805 0.83 ATR (0.66) ATRSCN2ASCN10AABL1BCR
SCHEMBL16420803 0.82 IRAK4 (0.63) ATRSCN2ASCN10AABL1BCR
SCHEMBL1792836 0.82 ATR (0.59) ATRGRM4PPARGABL1BCR
SCHEMBL2483560 0.81 ATR (1.00) ATRPRKDC
SCHEMBL16489075 0.81 ATR (0.69) ATRSCN2ASCN10AABL1BCR
SCHEMBL16420800 0.81 SCN2A (0.54) ATRSCN2ASCN10AABL1BCR
SCHEMBL14082560 0.81 CYP11B2 (0.65) ATRGRM4PPARGABL1BCR
SCHEMBL16420804 0.80 IRAK4 (0.69) ATRSCN2ASCN10AGRM4BRAF
SCHEMBL16489076 0.80 ATR (0.68) ATRSCN2ASCN10AABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885SCN2A 2823/4885SCN10A 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.